TOP TEN perturbations for 1552410_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552410_at
Selected probe(set): 1552410_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552410_at (1552410_at) across 6674 perturbations tested by GENEVESTIGATOR:

Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample

Relative Expression (log2-ratio):2.5963726
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal plasmocytoid dendritic cell sample
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population.

esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)

Relative Expression (log2-ratio):2.4359655
Number of Samples:2 / 3
Experimental esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).

bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-2.4263678
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondrosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-2.314724
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-2.2877789
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

rheumatoid arthritis study 37 (mono; CD14+ CD16+) / rheumatoid arthritis study 37 (mono; CD14+ CD16-)

Relative Expression (log2-ratio):2.1654577
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 37 (mono; CD14+ CD16+)
Peripheral blood CD14+ CD16+ monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm
Control rheumatoid arthritis study 37 (mono; CD14+ CD16-)
Peripheral blood CD14+ CD16- monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm

asthma study 22 (eosinophilic AIP) / asthma study 22 (paucigranulocytic AIP)

Relative Expression (log2-ratio):1.8510036
Number of Samples:15 / 10
Experimental asthma study 22 (eosinophilic AIP)
Sputum samples from asthmatic patients with eosinophilic airway inflammatory phenotype (AIP).
Control asthma study 22 (paucigranulocytic AIP)
Sputum samples from asthmatic patients with paucigranulocytic airway inflammatory phenotype (AIP).

asthma study 22 (mixed granulocytic AIP) / asthma study 22 (paucigranulocytic AIP)

Relative Expression (log2-ratio):1.5889673
Number of Samples:5 / 10
Experimental asthma study 22 (mixed granulocytic AIP)
Sputum samples from asthmatic patients with mixed granulocytic airway inflammatory phenotype (AIP).
Control asthma study 22 (paucigranulocytic AIP)
Sputum samples from asthmatic patients with paucigranulocytic airway inflammatory phenotype (AIP).

MALT lymphoma study 2 / normal spleen tissue

Relative Expression (log2-ratio):-1.5793743
Number of Samples:6 / 6
Experimental MALT lymphoma study 2
Human t(11;18)-positive mucosa-associated lymphoid tissue (MALT) lymphoma cells.
Control normal spleen tissue
Normal human spleen tissue sample.

monocyte activation study 1 (NOD2L/TLR/1L; 6h) / untreated monocyte sample (6h)

Relative Expression (log2-ratio):-1.4575987
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L/TLR/1L; 6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control untreated monocyte sample (6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 6 hours for RNA isolation.